Anglo-Norwegian health care group Nycomed Amersham has agreed to sellits Scandinavian pharmaceuticals subsidiary Nycomed Pharma to a new company, which will be 70% owned by private equity group Nordic Capital, for L340 million ($547.2 million). Nycomed will own 30% of the new entity once it reinvests L21 million for its equity interest and after the transaction is completed, its immediate cash proceeds will be L275 million.
Nycomed's chief executive Bill Castell said that the company can now focus on its imaging and life sciences units, and claimed that the group is "delighted to have found such a good home for our pharmaceuticals business." Industry observers believe that the sale paves the way for Nycomed to buy out Pharmacia & Upjohn's 45% stake in Amersham Pharmacia Biotech.
Nycomed Pharma had sales of L270 million and postoperating profits of L37.7 million in 1998. Hakan Bjorklund, formerly regional director for Northern Europe at Astra, has been appointed as chief executive and the company says it aims to list the new company within five years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze